AbbVie Inc. and OSE Immunotherapeutics, a clinical-stage immunotherapy company, entered a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in preclinical development.
 
OSE-230 is a first-in-class monoclonal antibody designed to activate ChemR23, a G-Protein Coupled Receptor (GPCR) target. Activation of ChemR23 may offer a novel mechanism for the resolution of chronic inflammation, modulating functions of both macrophages and neutrophils.
 
AbbVie will receive an exclusive global license to develop, manufacture and commercialize OSE-230. OSE Immunotherapeutics will receive a $48 million upfront and will be eligible to receive up to an additional $665 million in clinical development, regulatory and commercial milestones. OSE will be eligible to receive potential royalties on global sales.
 
“This collaboration underscores our commitment to expanding our immunology portfolio with the ultimate goal of improving the standard of care for patients living with inflammatory diseases globally,” said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. “By leveraging our expertise in immunology drug development, we look forward to advancing OSE-230, which offers a novel mechanism-of-action to treat chronic inflammation.”
 
“We are very pleased to collaborate with AbbVie, a global leader in the development and commercialization of innovative medicines, to drive our OSE-230 program forward,” said Nicolas Poirier, chief executive officer, OSE Immunotherapeutics. “This partnership represents a major milestone in our company’s progress and recognizes the value of our innovative R&D capabilities. I would like to thank all our employees who helped us reach this milestone through dedication and hard work.”